A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...